XTL Biopharma files to raise $40m on Nasdaq
Wellington Management has become a party of interest in Teva with a 6.1% stake, the company's expanded financial report for 2012 shows.
Boston-based private equity fund Wellington Management Company LLP has become a party at interest in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), with a 6.1% stake, according to the company's expanded financial report for 2012, published yesterday. Wellington Management is the largest institutional investor in Teva, in which no shareholder owns more than 5%. Wellington Management's stake is currently worth $2.17 billion.
Teva chairman Dr. Phillip Frost owns 1.54% of the company's shares, worth $545 million. Last year, Teva's general shareholders meeting approved a pay hike and reimbursement of travel expenses in 2011 for a total of $1.9 million. Teva also rents an office in Miami from a Frost-owned company for $412,000 a year. Rent will rise by 4% a year through 2015.
The aggregate salary cost of five executives who left Teva last year (including former CEO Shlomo Yanai) was $14.7 million, and they also exercised options and vested shares at a profit of $1.8 million. Current executives exercised options and vested shares at a profit of $4 million.
Teva's share price fell 11% in 2012, and was traded at an average share price of $41.10. The drop in the share price resulted in only 704,000 options being exercised by employees during the year - 70% fewer than in 2011 and 90% fewer than in 2010. The average strike price in 2012 was $33.36, resulting in a benefit of $5.5 million, down from $34 million in 2011.
The fall in Teva's share price means that 3.2 million options have a strike price higher than the current share price, effectively wiping them out. During the year, Teva allotted 7.2 million options at an average strike price of $40.50, 4% higher than yesterday's closing price on the NYSE of $38.94. Teva employees held 36.6 million options at the end of 2012.
The drop in the share price also affected Teva's share buybacks last year. The average buyback price fell from $44.60 per share in February to $36.60 in December. Altogether, the company bought back 28.1 million shares for $1.17 billion.
Teva had 45,948 employees worldwide at the end of 2012, 16% of whom were in Israel. The number of Israeli employees increased by 4% last year. The company's Kfar Saba facility had 1,021 employees, making it Teva's fifth largest facility by manpower, after the facilities in Germany, Japan, the Czech Republic, and Hungary.
The financial report also states that Teva's inventory rose 10% to $5.5 billion at the end of 2012 from $5 billion a year earlier. The company said that it has improved its inventory control, and has moderated this growth.
Published by Globes [online], Israel business news - www.globes-online.com - on February 13, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.